MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Corcept Therapeutics Incorporated Current Ratio 2011-2025 | CORT
Annual Current Ratio Corcept Therapeutics Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.22 | 5.41 | 7.15 | 8.84 | 11.8 | 7.91 | 6.66 | 4.2 | 2.4 | 2.35 | 2.23 | 4.58 | 11.4 | 7.91 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.8 | 2.23 | 6.29 |
Quarterly Current Ratio Corcept Therapeutics Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.3 | 4.83 | 5.19 | 5.39 | 6.04 | 6.07 | 4.49 | 5.09 | 7 | - | 8.9 | - | 7.76 | 8.84 | 13 | 12.4 | 13.3 | 11.8 | 11.8 | 11.8 | 11.8 | 10 | 10 | 10 | 10 | 8.7 | 8.7 | 8.7 | 8.7 | 7.46 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.3 | 4.3 | 8.65 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
3.76 | $ 4.86 | 3.08 % | $ 807 M |  Canada |
 |
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
3.4 | $ 3.22 | -1.08 % | $ 249 M |  USA |
 |
AlloVir
ALVR
|
22.6 | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
1.44 | $ 1.05 | -7.08 % | $ 290 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.76 | $ 0.27 | -4.88 % | $ 588 M |  Israel |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | USA |
 |
Catalyst Biosciences
CBIO
|
3.06 | $ 13.58 | -3.62 % | $ 894 M | USA |
 |
Ascendis Pharma A/S
ASND
|
0.918 | $ 216.09 | -1.96 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
2.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
7.02 | $ 3.14 | -4.15 % | $ 7.55 B |  Australia |
 |
Celldex Therapeutics
CLDX
|
17.5 | $ 27.1 | -1.51 % | $ 1.75 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
6.88 | $ 24.27 | 2.75 % | $ 2.87 B | USA |
 |
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M |  France |
 |
CureVac N.V.
CVAC
|
2.47 | $ 5.02 | -0.59 % | $ 934 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - |  Russia |
 |
BioVie
BIVI
|
8.46 | $ 1.4 | -3.45 % | $ 2.07 M | USA |
 |
ARCA biopharma
ABIO
|
28.7 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
13.4 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.16 | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
7.22 | $ 93.87 | -0.99 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
6.71 | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
2.39 | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
2.67 | - | - | $ 2.17 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
2.53 | $ 10.8 | - | $ 1.4 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.41 | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.87 | $ 26.2 | 3.68 % | $ 1.27 B | USA |
 |
Applied Molecular Transport
AMTI
|
2.31 | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
14.4 | $ 9.57 | 0.1 % | $ 140 M | USA |
 |
Eton Pharmaceuticals
ETON
|
1.95 | $ 15.96 | -4.42 % | $ 409 M | USA |
 |
Evogene Ltd.
EVGN
|
4.78 | $ 1.07 | -0.51 % | $ 27.9 M | Israel |
 |
Exelixis
EXEL
|
4.19 | $ 41.43 | 1.35 % | $ 12 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
10.8 | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
2.38 | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
0.41 | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
3.27 | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
15.9 | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
2.08 | $ 548.8 | -2.74 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
6.43 | - | - | $ 7.46 M | Israel |
|
Foghorn Therapeutics
FHTX
|
0.862 | $ 4.36 | -1.8 % | $ 239 M | USA |
 |
Aytu BioScience
AYTU
|
1.47 | $ 2.39 | 3.91 % | $ 15 M | USA |
 |
AstraZeneca PLC
AZN
|
1.65 | $ 91.03 | 1.34 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
1.61 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
5.28 | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
2.14 | $ 8.85 | -1.72 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
2.29 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
0.612 | $ 11.36 | -1.47 % | $ 735 M | USA |
 |
Biogen
BIIB
|
2.47 | $ 174.34 | 0.14 % | $ 25.4 B | USA |